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Abstract 
 
It has been 10 years since machine learning was first applied to neuroimaging data in 
psychiatric disorders to identify diagnostic and prognostic markers at the level of the 
individual. Proof of concept findings in major depression have since been extended in 
international samples and are beginning to include hundreds of samples from multisite data. 
Neuroimaging provides the unique capability to detect an acute depressive state in major 
depression, while we would not expect perfect classification with current diagnostic criteria 
which are based solely on clinical features. We review developments and the potential 
impact of heterogeneity, as well as homogeneity, on classification for diagnosis and 
prediction of clinical outcome. It is likely that there are distinct biotypes which comprise the 
disorder and which predict clinical outcome. Neuroimaging-based biotypes could aid in 
identifying the illness in individuals who are unable to recognise their illness and perhaps to 
identify the treatment resistant form early in the course of the illness. We propose that 
heterogeneous symptom profiles can arise from a limited number of neural biotypes and that 
apparently heterogeneous clinical outcomes include a common baseline predictor and 
common mechanism of treatment. Baseline predictors of clinical outcome reflect factors 
which indicate the general likelihood of response as well as those which are selective for a 
particular form of treatment. Irrespective of the mechanism, the capacity for response will 
moderate the outcome, which includes inherent models of interpersonal relationships that 
could be associated with genetic risk load and represented by patterns of functional and 
structural neural correlates as a predictive biomarker. We propose that methods which 
directly address heterogeneity are essential and that a synergistic combination could bring 
together data-driven inductive and symptom-based deductive approaches. Through this 
iterative process, major depression can develop from being syndrome characterized by a 
collection of symptoms to a disease with an identifiable pathophysiology. 
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Major depression is characterized by a persistent low mood or inability to experience usual 
feelings of pleasure, which is associated with impairments in neurovegetative, psychomotor 
and cognitive functioning (1, 2).  Although melancholia has been recognised throughout 
millennia, current diagnostic criteria are the result of attempts in the past decades to develop 
reliable, ontological classifications (3). However, the criteria are based only on observable 
clinical features because no diagnostic pathophysiology has yet been identified.  At the 
present time, major depression is thus a syndrome, which is characterized by a collection of 
symptoms, rather than a disease with an identifiable pathophysiology.  
 
There is significant heterogeneity in the symptom profiles that can make up a diagnosis, in 
the clinical outcomes for a given treatment, and in the longitudinal course for individual 
patients. Addressing heterogeneity is essential, which includes taking into account potential 
homogeneous factors. Within the heterogeneity in our current classification criteria, we 
support a core concept of the illness as a primary disorder in mood, in particular a lowering 
in mood that is embodied in the individual, though  we would not expect perfect classification 
with current diagnostic criteria (4).  
 
We propose that neuroimaging can aid in identifying potential biotypes by quantifying the 
heterogeneity, as well as homogeneity, that comprise major depression and the biotypes 
that can predict clinical outcome. We review development from the initial studies 10 years 
ago, which had applied machine learning to neuroimaging data to classify major depression  
and to predict clinical outcome (4–6), to replication and progression in international 
independent datasets (7–9), and how heterogeneity is being addressed in recent studies (7, 
10, 11). We review homogeneous mechanisms in psychological and pharmacological 
therapies, and we discuss the potential to identify biomarkers to predict clinical response. 
We propose that multitudinous heterogeneous symptom profiles can arise from a limited 
number of neural patterns as well as how apparently heterogeneous clinical outcomes can 
include a common baseline predictor of response and common mechanism of treatment.  
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We conclude with a proposal for the necessary steps and recent developments to identify 
neuroimaging-based biotypes: 1) harmonization of longitudinal multisite datasets acquired in 
different scanners and with different image acquisition protocols (12); 2) modelling the 
pathological process by multiple regularized transformations from the healthy to the patient 
population to identify the multiple neuroanatomical patterns that characterise disease 
heterogeneity (CHIMERA) (13); and 3) characterisation of the neuroanatomical 
heterogeneity through delineation of the multiple hyperplanes within disease populations 
(HYDRA) (14). 
 
Heterogeneity in major depression phenotypes 
 
Johannsen (15) introduced the terms: “genotype”, which describes the sum of genes in a 
gamete or zygote; “phenotype”, referring what can be readily observed; and “biotype”, which 
represents a given genotype in which biotypes can evolve from each other through small 
changes in genotype. Our current diagnosis of major depression is a phenotype, and many 
phenotypic combinations are possible within present diagnostic systems (1, 2). In terms of 
the symptoms, there are many potential combinations of clinical profiles, and there is 
significant clinical comorbidity with anxiety disorders (1–3). In terms of the longitudinal 
course of the illness, it is unknown whether the initial episode will be a single episode, or 
points to a course of unipolar depression, or is an acute depressive episode of a bipolar 
disorder (in the present review, ‘major depression’ refers to ‘unipolar depression’ in 
distinction to bipolar disorder). Heterogeneous phenotypes can arise from a common 
genotype, and seemingly homogeneous phenotypes can arise from different genotypes (15).  
 
Major depression is the leading mental health disorder worldwide, affecting over 350 million 
people (16). Yet, heritability estimates are around 37% (17), which is relatively low in 
contrast to bipolar disorder and schizophrenia which have heritability estimates that are 
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consistently up to 90% from twin and molecular genetic studies (18). The heritability of major 
depression is polygenic, consisting of hundreds of variants and genes, each providing a 
small component to the genetic contribution, and samples have generally consisted of 
people of European ancestry (19). Genetic risk variants are not clinically useful at the level of 
the individual, and how genetic risk progresses into an acute depressive episode is unknown 
(20).  
 
The genetic and environmental factors that lead to major depression are expressed in subtle 
and widespread alterations in brain structure and brain function. Magnetic resonance 
imaging (MRI) has revealed effects in multiple networks, including in frontolimbic circuits and 
default mode network (21), which are evident in the first episode (22, 23) and supported by 
neuropathological abnormalities (24). Multivariate pattern analysis integrates the subtle and 
spatially distributed alterations into models, learning to categorise the patterns and then to 
identify them in new data. Applying machine learning, proof of concept data demonstrated 
the ability to identify major depression at the level of the individual with high sensitivity and 
specificity from structural MRI and task-based functional MRI data (5, 6, 25), and distinct 
models predicted clinical response at baseline before the start of treatment with measures of 
confidence of the accuracy of the predictions (26). 
 
Kambeitz et al. (8) meta-analysis of 33 international samples of major depression (n = 912) 
and healthy (n = 864) participants demonstrated an overall classification with 77% sensitivity 
and 78% specificity, based on structural MRI, resting state functional MRI, task-based 
functional MRI and diffusion tensor imaging. Most studies to date have generated 
dichotomous classification labels for diagnosis, either major depression or healthy control, 
primarily due to limited sample sizes of participants with major depression (n = 15-57) (8, 9).  
In the largest multisite sample to date, Drysdale et al. (7) were able to identify a number of 
subtype models based on resting state functional MRI data, which were then validated in 
independent samples. The models were developed from what would be considered a more 
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treatment-resistant form of depression, that is from participants with major depression (n = 
220) with active symptoms which had failed to respond to at least two antidepressant 
treatment trials and while taking medications. The models were then trained in the full 
sample of depression (n = 333) and healthy (n = 378) participants and further validated in 
independent samples of depression (n = 125) and healthy (n = 352) participants.  
 
A common pattern of altered connectivity was evident, which encompassed the ventromedial 
prefrontal, orbitofrontal and posterior cingulate cortices, insula, and subcortical regions, and 
distinct patterns of functional connectivity and clinical symptom profiles were revealed in four 
subtypes with high sensitivity and specificity (82 - 92%). Subtype 1 was associated with 
anxiety, early and middle insomnia, and anergia; subtype 2 was primarily associated with 
anergia; subtype 3 with anhedonia and psychomotor retardation; and subtype 4 with the 
highest levels of anxiety, early and middle insomnia, as well as anhedonia. The subtypes 
were not accounted for by depressive severity only as there were no significant differences 
in depressive severity scores in subtypes 1, 3 and 4, although there was a modest decrease 
in subtype 2.  Increased thalamic and frontostriatal connectivity associated with anhedonia 
and psychomotor retardation was most pronounced in subtypes 3 and 4.  Reduced fronto-
amygdala connectivity associated with anxiety was most severe in subtypes 1 and 4.  
Reduced connectivity in anterior cingulate and orbitofrontal regions involved in motivation 
associated with symptoms of anergia and fatigue were most evident in subtypes 1 and 2. By 
addressing heterogeneity, Drysdale et al. (7) represent an important step in identifying 
potential biotypes that comprise major depression.  
 
While the highest levels of sensitivity and specificity in classification have been achieved in 
the treatment-resistant form of depression (8, 9), these could be confounded by biological 
effects of treatment resistance and antidepressant medication on brain structure and 
function (27, 28). From a methodological perspective, Dinga et al. (29) suggest that the 
clustering algorithm had led to overfitting as their replication analysis could not generate 
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comparable statistically significant subtypes. However, the samples differ significantly in their 
clinical characteristics in terms of treatment resistance and depressive state, which are 
associated with distinct neural correlates (27, 28). Drysdale et al. (7) training sample had 
been based on treatment resistant depression in an acute episode, while Dinga et al. (29) 
sample (n = 178) was comprised of major depression, anxiety disorders, as well as comorbid 
depression and anxiety disorders, in which about half the sample were in remission or had 
mild symptoms. The training samples, while larger than the majority of studies to date, could 
have been sufficiently non-overlapping, were underpowered, and might reflect homogeneity 
in the neural biotypes of less treatment resistant forms of the illness that are in remission or 
with few symptoms and which present as heterogeneous clinical phenotypes (7, 29). 
 
As a corollary, treatment-resistant depression is currently a clinical diagnosis that refers to a 
depressive episode that does not improve despite a series of treatments. A predictor model 
of clinical and sociodemographic data has demonstrated an accuracy of 75% in identifying 
treatment resistant depression (30). Clinical features in the model though included duration 
of illness, lifetime duration of hospitalizations and number of depressive episodes, which 
precludes identification early in the course of the illness. If the treatment resistant biotype is 
present at the onset of the episode, rather than as a consequence of subsequent 
treatments, then the biotype might be identifiable early in the illness.  Low rates of remission, 
which is less than one third of treatment trials irrespective of the form of treatment (31,32), 
indicate that current treatments are insufficient and highlight a subgroup which consistently 
shows a limited or lack of clinical improvement, suggesting that the pathophysiology of 
treatment-resistant depression could already be present early in the course of illness. 
 
Common and distinct neural patterns between unipolar major depression and other 
disorders are another source of heterogeneity. Conjunction analysis of grey matter volumes 
has observed common reductions in anterior cingulate, dorsomedial and ventromedial 
prefrontal cortices and insula in unipolar depression and bipolar disorder relative to healthy 
9 
 
controls with additional reductions which included right middle frontal and left hippocampus 
in unipolar depression relative to bipolar disorder (21). Classification results have 
demonstrated a contribution of reduced grey matter volumes in the anterior cingulate in 
unipolar depression relative to bipolar disorder (33), although the datasets were based on 
different samples (21,33). 
 
In addition to the inherent heterogeneity in the disorder, demographic-related factors, such 
as age, sex and ethnicity, are potential variables which can be controlled for. Most studies 
have consisted of ethnically homogeneous samples, either predominantly Caucasian or 
Chinese, raising the issue of whether the models can be generalised to the wider patient 
population, although we have found proof of principle from a small community sample of 
African, Asian and Caucasian patients based on structural MRI (9). Furthermore, applying 
neuroimaging-based biotypes as a model of major depression for genetic studies could 
improve the specificity of identifying variants for major depression as well as from a greater 
ethnic diversity, addressing limitations associated with broader definitions of depression and 
current genetic studies which have been most often assessed in people of European 
ancestry (20). 
 
Heterogeneity in methodology is a controllable variable. Task-based functional MRI 
protocols focused on a cognitive task (25) show lower levels of classification accuracy 
relative to an emotion-based task (5), which is not unexpected in major depression. 
Overlooking task effects adds variability that is not random, which degrades the quality of the 
signal and introduces confounds in meta-analyses of classification biomarkers (8, 34).   
 
Heterogeneity (and homogeneity) in treatment mechanisms 
 
Selective serotonin reuptake inhibitor (SSRI) antidepressants enhance synaptic plasticity, in 
which the effects on mood might be moderated by environment (35, 36). Pharmacological 
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treatment is associated with increases in regional cerebral volumes, such as in the 
hippocampus (37). Hippocampal volume is reduced in major depression, which is evident in 
the first episode (23). SSRI treatment is associated with increased hippocampal volume (37), 
and an early increase in hippocampal volume following one week of treatment with a 
serotonin noradrenaline reuptake inhibitor (SNRI) antidepressant was predictive of clinical 
response (35), which could reflect enhancement in synaptic plasticity and neurogenesis (36, 
37). 
 
Psychotherapy is an effective treatment for an acute depressive episode, is the preferred 
form of treatment for many individuals with depression, and demonstrates a sustained 
benefit in preventing a subsequent depressive relapse (39-41). The most common forms of 
short term psychotherapy are cognitive behavior therapy, behavioral activation, interpersonal 
therapy, and psychodynamic psychotherapy. Distinct formulations and mechanisms have 
been proposed, however efficacy has either been comparable or no significant differences 
have been observed between treatments (42-46). Moreover, our understanding of the neural 
mechanisms is limited, and there have been remarkably few longitudinal studies of the 
neural correlates of psychotherapy in depression, about a quarter of the number of 
pharmacological studies (47, 48).  
  
The theoretical formulation of cognitive behavior therapy (CBT) proposes a cognitive triad of 
biased negative views of onself, one’s future and experiences in the outside world which 
leads to characteristic affective and behavioural symptoms (49). CBT attempts to intervene 
in this cycle by addressing negative cognitions: automatic thoughts (eg. “I’m a failure”) and 
dysfunctional attitudes (eg. “I should be happy all the time”) that in turn reflect schemas and 
core beliefs which organize new experiences. Cognitive change is a key mechanism in 
which modifying maladaptive cognitions leads to an improvement in mood (49, 50). 
Behavioral activation therapy focuses on behavioural change to increase engagement in 
constructive reinforcing activities and to reduce engagement in avoidance and withdrawal 
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behaviours which maintain depression. Behavioral activation refers to the process of 
changing behaviors in order to engage in positively reinforcing and adaptive activities, which 
has demonstrated efficacy as a stand-alone component of CBT (43, 51).  
 
Interpersonal therapy (IPT) is based on the premise that maladaptive communication 
processes impact negatively on mood. IPT seeks to address interpersonal difficulties 
common in depression, focusing on four main themes: bereavement related to the grief and 
loss of a significant other; role transition due to a life change which affects relationships, 
such as a new job or loss of functioning; interpersonal disputes in expectations in 
relationships with significant others; or interpersonal deficits which could be reflected in 
social isolation or difficulties in maintaining relationships (52). Short term psychodynamic 
psychotherapy applies support as well as insight to discuss internalized past relationships, 
intrapersonal patterns and current relationships. Psychodynamic psychotherapy considers 
how internalized past relationships and unconscious processes could impact on 
interpersonal relationships and day to day functioning to improve awareness of such 
processes which in turn aids in the ability to modify responses and behaviours in current 
behaviours and relationships (53). 
 
If a particular process is a mechanism, it is necessary to establish the temporal sequence 
such it is the specific process which leads to improvements in depressive symptoms (54). As 
a potential mechanism in CBT, a change in cognition would be expected to precede any 
improvements in depressive symptoms. In support, early changes in cognition during CBT 
and “sudden gains” (55–57) as well as therapist adherence to techniques and competence 
(58) are associated with symptom improvements. However, when changes in mood 
symptoms were taken into account, early changes in cognitive content no longer predicted 
subsequent improvements (59). Moreover, improvements in depressive symptoms have also 
been observed to precede changes in cognitions (60). Component analysis suggests that 
the effectiveness of CBT can be largely ascribed to behavioral activation (43, 50), while 
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acknowledging a predictive component of cognitive change, though assessed as a nominal 
contribution (61).  
 
Although heterogeneous mechanisms have been proposed, the effects are small. It is well 
established that common factors contribute to the efficacy of the different forms of 
psychotherapy. Therapeutic alliance refers to the relationship between the patient and 
therapist and has consistently demonstrated a mediating effect in clinical outcome to 
psychotherapy (62), as well as to pharmacological and placebo treatments (63, 64). Patient 
outcome expectations describe the prognostic beliefs about effects of engaging in treatment 
that could be positive, negative or ambivalent, which show a small association with treatment 
outcome, which may further be mediated by the therapeutic alliance (65). A common role of 
the therapist in short term psychotherapy is as an advocate for the patient. The CBT 
therapist is proposed to represent an active, authoritative advocate for change who supports 
patients to engage in activities and thoughts, which in turn leads to improvements in 
depressive symptoms (61). The goal of the IPT therapist is to be the patient’s ally who 
reinforces beneficial interpersonal skills and actively reviews adverse outcomes including 
through role play and rehearsal (52). A range of outcomes has been observed between 
therapists, in which adherence and competence seem to have a limited effect (66), while 
therapist adaptiveness and empathy are correlated with clinical outcome (68). How, when 
and what a therapist responds to in a session reflects their adaptiveness and empathy. 
 
Enhanced synaptic plasticity is a potential common mechanism of antidepressant medication 
(35, 36) and psychotherapy. Synaptic plasticity is a fundamental mechanism in learning and 
memory (68, 69), and learning is an important mechanism in psychotherapy, in which the 
therapist provides an essential component with whom skills are learned. Moreover, we 
propose that the patient therapist relationship builds upon inherent models of relationships. 
Even in the absence of a therapist who is physically present, we would expect that inherent 
models would have an impact on the perceived relationship, such as in internet-based 
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treatments. We propose that encoding of the relationship is episodic with the repeated 
sessions of the therapy and that recall of the relationship may be initially explicit. 
 
Furthermore, treatment with CBT (70) as well as treatment with a selective serotonin 
reuptake inhibitor antidepressant (71, 72) has been associated with normalisation of 
amygdala responses to sad emotional expressions. Encouragement and validation from 
another person is associated with a reduction in pain (73), in which the emotional-affective 
dimensions are encoded in the amygdala (74). While support is an inherent component of 
the patient therapist relationship in both psychological and pharmacological treatments, 
learning in the context of the patient therapist relationship is potential mechanism, which 
would have a greater contribution in psychotherapy. Normalisation of amygdala responses 
could reflect common effects on mood following psychological and pharmacological 
treatments, in which learning in the context of the patient therapist relationship is a 
contributing mechanism. 
 
Heterogeneity in treatment responsiveness and outcomes 
 
Baseline predictors of clinical outcome reflect factors which indicate the general likelihood of 
response to a variety of forms of treatments and those which are selective for a particular 
form of treatment. Irrespective of the mechanism of treatment, the capacity for response will 
moderate the outcome. If there is an inherent capacity, then there would be general predictor 
of clinical responsivity to current first line treatments (32, 35, 36, 47). The absence of such 
marker/s would indicate a reduced likelihood of response.  
 
Short term psychological treatments require the therapist to be an active advocate for the 
patient (49, 52, 53, 75). This could be explicit in the physical presence of the therapist or an 
inherent implicit presence. Therapeutic alliance is a mediator of treatment outcomes to both 
pharmacological and psychological treatments (62-65), but how an individual with 
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depression experiences the interaction with the therapist would be affected in part by their 
inherent patterns in interactions in close relationships (76, 77). Predisposing patterns in 
interpersonal relationships would moderate treatment outcome as a general predictor of 
clinical outcome. 
 
If impairments in inherent models of interpersonal relationships moderate clinical outcome to 
psychological treatments, then factors which impact on their development would contribute 
to clinical outcome, such as attachment patterns (76, 77). Spatial and temporal patterns of 
interactions between an individual and their attachment figures frame how the individual then 
perceives and responds in other interpersonal relationships, termed ‘internal working 
models’ (76). For example, attachment theory describes how interpersonal relationships 
evolve from relationships with early caregivers to diverse adult relationships, which are 
malleable and can continue to develop. It is estimated that 55% of healthy adults have a 
secure attachment pattern, but it is the insecure attachment profile which predominates in 
depression and specific subtypes have been associated with poorer clinical outcomes (76, 
77). 
 
Limited development of inherent models of interpersonal relationships could also be 
associated with genetic risk load, for example it might be expected that patients with 
depression with a high genetic risk load for autistic spectrum disorder would prefer an 
internet based CBT, however, if they have an impaired inherent model of interpersonal 
relationships, then their ability to interact with and utilise the CBT format would be limited 
(76), as potentially for any short term therapy which could be transdiagnostic. 
 
Shared features in the forms of therapy include treatment durations, which have mostly been 
short term in the order of weeks to months, low rates of clinical effectiveness, and the role of 
the therapist as an active advocate who interacts directly with the patient (32, 78). However, 
if the ability of the patient to engage with the therapist depends in part on their inherent 
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models of interpersonal relationships, then impairments in the models would impact on how 
their relationship develops with the therapist, to which some therapists may be better able to 
respond and adapt their treatment. This heterogeneity could be evident in part in amygdala 
responsivity, for example an insecure anxious attachment pattern is associated with 
increased amygdala response to emotional stimuli (79) and attachment patterns modulate 
experimentally induced pain ratings in the presence of an observer (80).  
 
Addressing heterogeneity 
 
Being able to identify an acute depressive episode in major depression that is not treatment-
resistant, to predict treatment outcome and to predict the course of the illness are key clinical 
challenges. Model development requires the appropriate data and methodology, which can 
be summarised, but the quality of the data and methodology are paramount (4, 10). In order 
to reflect clinical practice and to develop models that are not confounded by treatment, the 
data would be from a community based medication-free population in an acute depressive 
episode with first episode or recurrent depression that is not treatment-resistant. Well 
characterised large datasets are required with consideration of ethical and data sharing 
issues. We would not expect perfect classification with current diagnostic criteria because 
clinical presentations do not necessarily reflect specific biological measures and do not 
identify specific pathophysiologies. We would expect an iterative process in which the 
neuroimaging-based biomarkers are applied to specify potential pathophysiologies (4).  
 
Methods that directly address heterogeneity are essential. Several studies have begun to 
use high-dimensional clustering methods to dissect imaging heterogeneity in various 
diseases (81). While direct clustering of patient data can be informative, it is confounded by 
variations related to demographics and other factors that are not related to disease 
pathophysiology. Two semi-supervised learning methods are proposed in an attempt to 
address this limitation: CHIMERA (13)  and HYDRA (14).   
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CHIMERA is primarily generative, and it assumes that the statistical distribution of imaging 
features of the (heterogeneous) patient cohort is derived from the statistical distribution of 
the healthy cohort via a number of transformations that reflect the effects of underlying 
(heterogeneous) pathophysiologies (Figure 1). Covariates are taken into account explicitly. 
CHIMERA is probabilistic clustering approach that models the pathological process by a 
combination of multiple regularized transformations from the healthy control population to the 
patient population. The populations are considered as point distributions which are matched 
by a variant of the coherent point drift algorithm. For example, a 40 year old woman with 
depression would have been a 40 year old healthy woman had she been spared the 
disorder. This is directly modelled in CHIMERA which seeks to identify the multiple imaging 
patterns that relate to disease effects in order to characterize disease heterogeneity.  
 
HYDRA takes a similar approach, but from the discriminative angle: it uses a number of 
support vector machine hyperplanes to separate patients from health controls in which each 
hyperplane reflects one subtype. Covariates are first regressed out of the data. The 
subtypes are captured by multiple linear hyperplanes which form a convex polytope that 
separates two populations in which each face of the polytope defines a disease subtype 
(Figure 2). Both methods use cross-validation and split-sample analyses to find the optimal 
number of subtypes.  
 
The potential of these methods to capture neuroanatomical heterogeneity from MRI has 
been demonstrated in schizophrenia, mild cognitive impairment and Alzheimer’s disease 
(11, 81-83). Data-driven, inductive modelling strategies model the neuroanatomical patterns 
that make up major depression as a collection of directions of deviation from normal 
neuroanatomical patterns. These approaches model the pathological processes associated 
with depression by a combination of multiple regularized transformations from the healthy 
control population to the patient population, thereby seeking to identify multiple 
17 
 
neuroanatomical patterns that relate to disease effects and to characterize disease 
heterogeneity. A complementary deductive approach, such as reported clinical symptoms, 
would apply prior knowledge to identify the linear combinations of neuroanatomical features 
that correlate with clinical clusters. A synergistic combination could also bring together data-
driven inductive and symptom-based deductive approaches such that the clinical measures 
will be used in CHIMERA and HYDRA to inform the clustering.  
 
Psychological and pharmacological treatments propose distinct heterogeneous mechanisms. 
Yet, short term psychotherapies advocate an active therapist as a common homogeneous 
component. If outcomes to short term psychotherapy as well as to antidepressant 
medication depend in part on inherent models of interpersonal interactions, then this is 
measurable prior to the initiation of treatment. Measures to date though have been 
subjective or clinician-rated without a gold standard. Neuroimaging markers offer the 
potential to characterize the homogeneous as well as heterogeneous mechanisms of clinical 
effectiveness at the level of the individual with the potential to lead to patient-specific 
treatments.  
 
In summary, neuroimaging-based biomarkers offer the strongest potential to date in 
identifying the biotypes that comprise our current symptom-based diagnosis of major 
depression. Increasing sample sizes from multisite collaborations will provide increased 
power to identify neural biotypes that comprise the diagnosis. Among purported 
heterogeneous treatment mechanisms, a common factor is the patient clinician relationship. 
Learning in the context of this relationship is a potential common mechanism which could 
modulate amygdala responsivity. The inherent model of interpersonal relationships would 
moderate clinical outcome, which could be associated with genetic risk load and represented 
by patterns of functional and structural neural correlates. A predictive biomarker would aid in 
the stratification of the illness, indicating the most appropriated treatment or combination of 
treatments, which would improve recovery and disability, as well as increase statistical 
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power in treatment studies by reducing heterogeneity in samples. Integrating neuroimaging-
based biotypes with genetic studies could aid the specificity in identifying variants. It is 
essential to directly address heterogeneity in developing biomarkers in which a synergistic 
combination could bring together data-driven inductive and symptom-based deductive 
approaches.  
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Figure Legends 
 
Figure 1. 
CHIMERA is a primarily generative method, which assumes that the distribution of 
measurements from patients (Y, in the figure) is derived from the distribution of controls (X, 
in the figure), after some (unknown) transformations (T_i) are applied. The latter represent 
(heterogeneous) disease effects 
 
Figure 2. 
The HYDRA method is mostly discriminative, in that it attempts to separate patients and 
controls as well as possible, using multiple hyperplanes, one for each subtype. 
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